Verrica Pharmaceuticals announced positive topline results from its Phase III CAMP-1 and CAMP-2 pivotal trials with VP 102 (cantharidin 0.7%)...
Verrica Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for VP 102 (cantharidin 0.7% Topical Solution), a...
Verrica Pharmaceuticals Inc. announced that the Company received a letter from the FDA as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP 102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum.
Verrica Pharmaceuticals Inc. presented data from the company’s pivotal Phase III CAMP-1 and CAMP-2 trials of lead product candidate, VP...
Background and objectives: Primary hyperoxaluria type I (PH I) is caused by deficiency of the liver-specific enzyme alanine-glyoxylate:aminotransferase (AGT). Many mutations are known to perturb AGT protein folding. Vitamin B6 (B6) is the only specific drug available for treatment.
Verrica Pharmaceuticals Inc. announced that the FDA has issued a Complete Response Letter regarding its New Drug Application (NDA) for VP 102 for the treatment of molluscum contagiosum (molluscum).
Verrica Pharmaceuticals Inc. has announced that the FDA has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP 102 for the treatment of molluscum contagiosum (molluscum).
Purpose: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC).
Areas covered: This article summarizes published case series in which givosiran, a subcutaneously administered small interfering RNA approved for AHP treatment, appeared to exacerbate dysregulated homocysteine metabolism in patients with AHP.